820 MCLA-145 is a bispecific IgG1 antibody that inhibits PD-1/PD-L1 signaling while simultaneously activating CD137 signaling on T cells
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1818724999379288064 |
|---|---|
| author | Jing Zhou Mark Throsby Lex Bakker Arpita Mondal Wilfred Marissen Paul Tacken Steef Engels Liang-Chuan Wang Patrick Mayes Cecile Geuijen Rinse Klooster Pieter Fokko Van Loo Yao-Bin Liu Arjen Kramer Thomas Condamine Alla Volgina Linda Hendriks Hans van der Maaden Eric Rovers Floris Fransen Renate den Blanken-Smit Vanessa Zondag-van der Zande Abdul Basmeleh Willem Bartelink Ashwini Kulkarni Cheng-Yen Huang Leslie Hall Shane Harvey Chrysi Kanellopoulou Shaun Stewart Horacio Nastri Ton Logtenberg Simon Plyte |
| author_facet | Jing Zhou Mark Throsby Lex Bakker Arpita Mondal Wilfred Marissen Paul Tacken Steef Engels Liang-Chuan Wang Patrick Mayes Cecile Geuijen Rinse Klooster Pieter Fokko Van Loo Yao-Bin Liu Arjen Kramer Thomas Condamine Alla Volgina Linda Hendriks Hans van der Maaden Eric Rovers Floris Fransen Renate den Blanken-Smit Vanessa Zondag-van der Zande Abdul Basmeleh Willem Bartelink Ashwini Kulkarni Cheng-Yen Huang Leslie Hall Shane Harvey Chrysi Kanellopoulou Shaun Stewart Horacio Nastri Ton Logtenberg Simon Plyte |
| author_sort | Jing Zhou |
| collection | DOAJ |
| first_indexed | 2024-12-17T21:35:20Z |
| format | Article |
| id | doaj.art-3ac9962628b4422ba42992da2d11038e |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-12-17T21:35:20Z |
| publishDate | 2020-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-3ac9962628b4422ba42992da2d11038e2022-12-21T21:31:46ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0820820 MCLA-145 is a bispecific IgG1 antibody that inhibits PD-1/PD-L1 signaling while simultaneously activating CD137 signaling on T cellsJing Zhou0Mark Throsby1Lex Bakker2Arpita Mondal3Wilfred Marissen4Paul Tacken5Steef Engels6Liang-Chuan Wang7Patrick Mayes8Cecile Geuijen9Rinse Klooster10Pieter Fokko Van Loo11Yao-Bin Liu12Arjen Kramer13Thomas Condamine14Alla Volgina15Linda Hendriks16Hans van der Maaden17Eric Rovers18Floris Fransen19Renate den Blanken-Smit20Vanessa Zondag-van der Zande21Abdul Basmeleh22Willem Bartelink23Ashwini Kulkarni24Cheng-Yen Huang25Leslie Hall26Shane Harvey27Chrysi Kanellopoulou28Shaun Stewart29Horacio Nastri30Ton Logtenberg31Simon Plyte32Center of Severe Acute Pancreatitis (CSAP), Department of General Surgery, Jinling Hospital, Nanjing University Medical School, Nanjing, Jiangsu, ChinaAff394 Merus N.V. Utrecht Netherlands Aff394 Merus N.V. Utrecht Netherlands Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA1Merus N.V., Utrecht, Netherlands1Merus N.V., Utrecht, Netherlands1Merus N.V., Utrecht, Netherlands3Incyte Corporation, Wilmington, DE, USA3Incyte Corporation, Wilmington, DE, USA1Merus N.V., Utrecht, Netherlands1Merus NV, Utrecht, Netherlands1Merus NV, Utrecht, Netherlands1Merus NV, Utrecht, Netherlands1Merus NV, Utrecht, Netherlands2Incyte Corporation, Wilmington, DE, USA2Incyte Corporation, Wilmington, DE, USA1Merus NV, Utrecht, Netherlands1Merus NV, Utrecht, Netherlands1Merus NV, Utrecht, Netherlands1Merus NV, Utrecht, Netherlands1Merus NV, Utrecht, Netherlands1Merus NV, Utrecht, Netherlands1Merus NV, Utrecht, Netherlands1Merus NV, Utrecht, Netherlands2Incyte Corporation, Wilmington, DE, USA2Incyte Corporation, Wilmington, DE, USA2Incyte Corporation, Wilmington, DE, USA2Incyte Corporation, Wilmington, DE, USA2Incyte Corporation, Wilmington, DE, USA2Incyte Corporation, Wilmington, DE, USA2Incyte Corporation, Wilmington, DE, USA1Merus NV, Utrecht, Netherlands1Merus NV, Utrecht, Netherlands |
| spellingShingle | Jing Zhou Mark Throsby Lex Bakker Arpita Mondal Wilfred Marissen Paul Tacken Steef Engels Liang-Chuan Wang Patrick Mayes Cecile Geuijen Rinse Klooster Pieter Fokko Van Loo Yao-Bin Liu Arjen Kramer Thomas Condamine Alla Volgina Linda Hendriks Hans van der Maaden Eric Rovers Floris Fransen Renate den Blanken-Smit Vanessa Zondag-van der Zande Abdul Basmeleh Willem Bartelink Ashwini Kulkarni Cheng-Yen Huang Leslie Hall Shane Harvey Chrysi Kanellopoulou Shaun Stewart Horacio Nastri Ton Logtenberg Simon Plyte 820 MCLA-145 is a bispecific IgG1 antibody that inhibits PD-1/PD-L1 signaling while simultaneously activating CD137 signaling on T cells Journal for ImmunoTherapy of Cancer |
| title | 820 MCLA-145 is a bispecific IgG1 antibody that inhibits PD-1/PD-L1 signaling while simultaneously activating CD137 signaling on T cells |
| title_full | 820 MCLA-145 is a bispecific IgG1 antibody that inhibits PD-1/PD-L1 signaling while simultaneously activating CD137 signaling on T cells |
| title_fullStr | 820 MCLA-145 is a bispecific IgG1 antibody that inhibits PD-1/PD-L1 signaling while simultaneously activating CD137 signaling on T cells |
| title_full_unstemmed | 820 MCLA-145 is a bispecific IgG1 antibody that inhibits PD-1/PD-L1 signaling while simultaneously activating CD137 signaling on T cells |
| title_short | 820 MCLA-145 is a bispecific IgG1 antibody that inhibits PD-1/PD-L1 signaling while simultaneously activating CD137 signaling on T cells |
| title_sort | 820 mcla 145 is a bispecific igg1 antibody that inhibits pd 1 pd l1 signaling while simultaneously activating cd137 signaling on t cells |
| work_keys_str_mv | AT jingzhou 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT markthrosby 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT lexbakker 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT arpitamondal 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT wilfredmarissen 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT paultacken 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT steefengels 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT liangchuanwang 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT patrickmayes 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT cecilegeuijen 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT rinseklooster 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT pieterfokkovanloo 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT yaobinliu 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT arjenkramer 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT thomascondamine 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT allavolgina 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT lindahendriks 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT hansvandermaaden 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT ericrovers 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT florisfransen 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT renatedenblankensmit 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT vanessazondagvanderzande 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT abdulbasmeleh 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT willembartelink 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT ashwinikulkarni 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT chengyenhuang 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT lesliehall 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT shaneharvey 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT chrysikanellopoulou 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT shaunstewart 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT horacionastri 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT tonlogtenberg 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells AT simonplyte 820mcla145isabispecificigg1antibodythatinhibitspd1pdl1signalingwhilesimultaneouslyactivatingcd137signalingontcells |